Discovery of pyridyl sulfonamide 11-beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors for the treatment of metabolic disorders

被引：15

作者：

Yoon, David S. ^{[1
]}

Wu, Shung C. ^{[1
]}

Seethala, Ramakrishna ^{[2
]}

Golla, Rajasree ^{[2
]}

Nayeem, Akbar ^{[3
]}

Everlof, John G. ^{[4
]}

Gordon, David A. ^{[5
]}

Hamann, Lawrence G. ^{[1
]}

Robl, Jeffrey A. ^{[1
]}

机构：

[1] Bristol Myers Squibb Co, Res & Dev, Dept Chem, Princeton, NJ 08543 USA

[2] Bristol Myers Squibb Co, Res & Dev, Lead Evaluat, Princeton, NJ 08543 USA

[3] Bristol Myers Squibb Co, Res & Dev, CADD, Princeton, NJ 08543 USA

[4] Bristol Myers Squibb Co, Res & Dev, PCO Discovery Pharmaceut, Princeton, NJ 08543 USA

[5] Bristol Myers Squibb Co, Res & Dev, Dept Biol, Princeton, NJ 08543 USA

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2014年 / 24卷 / 21期

关键词：

11-Beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1); Enzyme inhibitor; Pyridyl sulfonamide; Type-2; diabetes; SELECTIVE INHIBITORS; VISCERAL OBESITY; POTENT; HYPERGLYCEMIA; DESIGN; MODEL; MICE;

D O I：

10.1016/j.bmcl.2014.09.012

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A previous disclosure from this lab highlighted the discovery of pyridyl amides as potent 11 beta-HSD1 inhibitors. In order to build additional novelty and polarity into this chemotype, replacement of the hydrogen-bonding carbonyl (CO) pharmacophore with the bioisosteric sulfonyl (SO2) group was examined. Despite initial comparisons suggesting the corresponding sulfonamides exhibited weaker activity versus their carbonyl counterparts, further optimization was performed in an effort to identify various potent and unique leads for the program. Judicious incorporation of polar moieties resulted in the identification of compounds with enhanced potency and lipophilicity profiles, resulting in leads with superior aqueous solubility and liver microsomal stability. (C) 2014 Elsevier Ltd. All rights reserved.

引用

页码：5045 / 5049

页数：5

共 50 条

[21] Discovery of camphor-derived pyrazolones as 11β-hydroxysteroid dehydrogenase type 1 inhibitors
Gillespie, Paul
Pietranico-Cole, Sherrie
Myers, Michael
Bilotta, Joseph A.
Conde-Knape, Karin
Fotouhi, Nader
Goodnow, Robert A., Jr.
Guertin, Kevin R.
Hamilton, Matthew M.
Haynes, Nancy-Ellen
Liu, Baolian
Qi, Lida
Ren, Yonglin
Scott, Nathan R.
So, Sung-Sau
Spence, Cheryl
Taub, Rebecca
Thakkar, Kshitij
Tilley, Jefferson W.
Zwingelstein, Catherine
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2014, 24 (12) : 2707 - 2711
[22] Discovery of Adamantyl Heterocyclic Ketones as Potent 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitors
Su, Xiangdong
Vicker, Nigel
Thomas, Mark P.
Pradaux-Caggiano, Fabienne
Halem, Heather
Culler, Michael D.
Potter, Barry V. L.
CHEMMEDCHEM, 2011, 6 (08) : 1439 - 1451
[23] Functional Effects of Polymorphisms in the Human Gene Encoding 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1): A Sequence Variant at the Translation Start of 11β-HSD1 Alters Enzyme Levels
Malavasi, Elise L. V.
Kelly, Val
Nath, Nikita
Gambineri, Alessandra
Dakin, Rachel S.
Pagotto, Uberto
Pasquali, Renato
Walker, Brian R.
Chapman, Karen E.
ENDOCRINOLOGY, 2010, 151 (01) : 195 - 202
[24] Free-Wilson and Structural Approaches to Co-optimizing Human and Rodent Isoform Potency for 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors
Goldberg, Frederick W.
Leach, Andrew G.
Scott, James S.
Snelson, Wendy L.
Groombridge, Sam D.
Donald, Craig S.
Bennett, Stuart N. L.
Bodin, Cristian
Gutierrez, Pablo Morentin
Gyte, Amy C.
JOURNAL OF MEDICINAL CHEMISTRY, 2012, 55 (23) : 10652 - 10661
[25] The discovery of azepane sulfonamides as potent 11β-HSD1 inhibitors
Neelamkavil, Santhosh F.
Boyle, Craig D.
Chackalamannil, Samuel
Greenlee, William J.
Zhang, Lili
Terracina, Giuseppe
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (16) : 4563 - 4565
[26] Discovery of novel inhibitors of human 11β-hydroxysteroid dehydrogenase type 1
Su, Xiangdong
Vicker, Nigel
Trusselle, Melanie
Halem, Heather
Culler, Michael D.
Potter, Barry V. L.
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2009, 301 (1-2) : 169 - 173
[27] Discovery and optimization of piperidyl benzamide derivatives as a novel class of 11β-HSD1 inhibitors
Rew, Yosup
McMinn, Dustin L.
Wang, Zhulun
He, Xiao
Hungate, Randall W.
Jaen, Juan C.
Sudom, Athena
Sun, Daqing
Tu, Hua
Ursu, Stefania
Villemure, Elisia
Walker, Nigel P. C.
Yan, Xuelei
Ye, Qiuping
Powers, Jay P.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (06) : 1797 - 1801
[28] The development and SAR of pyrrolidine carboxamide 11β-HSD1 inhibitors
Cheng, Hengmiao
Hoffman, Jacqui
Le, Phuong
Nair, Sajiv K.
Cripps, Stephan
Matthews, Jean
Smith, Christopher
Yang, Michele
Kupchinsky, Stan
Dress, Klaus
Edwards, Martin
Cole, Bridget
Walters, Evan
Loh, Christine
Ermolieff, Jacques
Fanjul, Andrea
Bhat, Ganesh B.
Herrera, Jocelyn
Pauly, Tom
Hosea, Natilie
Paderes, Genevieve
Rejto, Paul
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2010, 20 (09) : 2897 - 2902
[29] Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors
Webster, Scott P.
Ward, Peter
Binnie, Margaret
Craigie, Eilidh
McConnell, Kirsty M. M.
Sooy, Karen
Vinter, Andy
Seckl, Jonathan R.
Walker, Brian R.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (10) : 2838 - 2843
[30] Evaluation of selective inhibitors of 11β-HSD1 for the treatment of hypertension
Bauman, David R.
Whitehead, Alan
Contino, Lisa C.
Cui, Jisong
Garcia-Calvo, Margarita
Gu, Xin
Kevin, Nancy
Ma, Xiuying
Pai, Lee-yuh
Shah, Kashmira
Shen, Xiaolan
Stribling, Sloan
Zokian, Hratch J.
Metzger, Joe
Shevell, Diane E.
Waddell, Sherman T.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2013, 23 (12) : 3650 - 3653

← 1 2 3 4 5 →